Document is current
Any future updates will be listed below
-
Authors
Jiménez-Vacas, Juan M.
Westaby, Daniel
Figueiredo, Ines https://orcid.org/0009-0007-2754-5608
De Haven Brandon, Alexis
Padilha, Ana
Yuan, Wei https://orcid.org/0000-0001-8004-1846
Seed, George https://orcid.org/0000-0002-1105-1781
Bogdan, Denisa
Gurel, Bora https://orcid.org/0000-0002-5018-8078
Bertan, Claudia
Miranda, Susana https://orcid.org/0000-0002-5936-2706
Lambros, Maryou
Montero-Hidalgo, Antonio J. https://orcid.org/0000-0002-1948-7512
Coleman, Ilsa
Yu, Ivan Pak Lok
Buroni, Lorenzo
Zeng, Wanting https://orcid.org/0000-0002-4101-1502
Neeb, Antje J.
Welti, Jon
Rekowski, Jan https://orcid.org/0000-0002-5207-3864
Paravati, Roberta
Gabel, Florian
Pandell, Nicole
Ferreira, Ana
Crespo, Mateus https://orcid.org/0000-0003-4043-8296
Riisnaes, Ruth
Das, Souvik
Taylor, Joe
Waldron, Nick
Hobern, Emily
Valenti, Melanie
Ning, Jian
Bernett, Ilona
Liodaki, Kate
Persse, Thomas
Galipeau, Patricia https://orcid.org/0000-0001-7961-7430
Wilkinson, Scott https://orcid.org/0000-0002-2613-8425
Trostel, Shana Y.
Karzai, Fatima https://orcid.org/0000-0002-3244-1332
Chau, Cindy H. https://orcid.org/0000-0002-6928-3833
Beatson, Erica L.
Zhang, Xiaohu
Klumpp-Thomas, Carleen https://orcid.org/0000-0002-6646-6132
Varkaris, Andreas
Luque, Raul M.
Swain, Amanda https://orcid.org/0000-0001-8666-1608
Raynaud, Florence https://orcid.org/0000-0003-0957-6279
Lack, Nathan A. https://orcid.org/0000-0001-7399-5844
Thomas, Craig J. https://orcid.org/0000-0001-9386-9001
Ha, Gavin https://orcid.org/0000-0001-7578-7272
Figg, William D. https://orcid.org/0000-0003-2428-5613
Bezzi, Marco
Sowalsky, Adam G. https://orcid.org/0000-0003-2760-1853
Nelson, Peter S. https://orcid.org/0000-0002-5451-5726
Carreira, Suzanne https://orcid.org/0000-0002-5077-5379
Balk, Steven P. https://orcid.org/0000-0002-4546-7371
de Bono, Johann S. https://orcid.org/0000-0002-2034-595X
Sharp, Adam https://orcid.org/0000-0002-3740-1612
-
Funding
Funding for this research was provided by:
Royal Society of Medicine (IES\R3\213131)
Prostate Cancer Foundation (Challenge Award)
Wellcome Trust (Clinical Research Career Development Fellowship)
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 4 September 2025
First Online: 8 October 2025
Competing interests
: J.M.J.-V., D.W., I.F., A.d.H.V., A.P., W.Y., G.S., D.B., B.G., C.B., S.M., L.B., W.Z., A.J.N., J.W., J.R., R.P., A.F., M.C., R.R., S.D., J.T., E.H., M.V., J.N., K.L., A.S., F.R., S.C., J.S.d.B. and A.Sharp are employees of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). A.G.S. reports that the National Cancer Institute (NCI) has a Cooperative Research and Development Agreement (CRADA) with Astellas. Resources are provided by this CRADA to the NCI. A.G.S. gets no personal funding from this CRADA but is the primary investigator of the CRADA. J.S.d.B. has served on advisory boards and received fees from many companies, including Amgen, Astra Zeneca, Bayer, Bioxcel Therapeutics, Daiichi, Genentech/Roche, GSK, Merck Serono, Merck Sharp & Dohme, Pfizer, and Sanofi Aventis. He is an employee of the ICR, which has received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, Vertex. J.S.d.B. was named as an inventor, with no financial interest, for patent 8,822,438, submitted by Janssen, that covers the use of abiraterone acetate with corticosteroids. J.S.d.B. has been the CI/PI of many industry-sponsored clinical trials. A.Sharp has received travel support from Sanofi, Roche-Genentech and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research, CHARM Therapeutics, Ellipses Pharma and Droia Ventures. A.Sharp has been the CI/PI of industry-sponsored clinical trials. The remaining authors declare no conflicts of interest.
